Teriparatide

Overview

Teriparatide is an FDA-approved anabolic bone-building agent consisting of the first 34 amino acids of parathyroid hormone. Unlike antiresorptive osteoporosis drugs that slow bone loss, teriparatide actively stimulates new bone formation. The key to its mechanism is intermittent exposure: while continuous PTH causes bone resorption, daily injections stimulate osteoblasts more than osteoclasts, resulting in net bone formation. Clinical trials show 8% spine bone density increases and 65% reduction in vertebral fractures.

Mechanism of action

Teriparatide binds to PTH type 1 receptors (G-protein coupled receptors) on osteoblasts, osteocytes, and renal tubular cells. This activates PKA and PKC signaling pathways that promote osteoblast activity. The intermittent daily dosing creates an ‘anabolic window’ where bone formation exceeds resorption. Teriparatide upregulates IGF-1 and FGF2 expression, stimulates bone formation on trabecular and cortical surfaces, and increases bone mineral density through preferential osteoblast stimulation.

Key research findings

• FDA-approved for osteoporosis treatment
• Actively builds new bone (anabolic)
• Increases spine bone density by 5-9%
• Reduces vertebral fracture risk by 65%
• Reduces nonvertebral fractures by 35%
• Works differently than antiresorptive drugs
• Benefits seen within 3 months
• Creates ‘anabolic window’ for bone growth

Research applications

Osteoporosis (FDA-Approved)

• Postmenopausal Osteoporosis — FDA-approved for women with osteoporosis at high risk of fracture.
• Male Osteoporosis — FDA-approved for men with primary or hypogonadal osteoporosis at high risk.
• Glucocorticoid-Induced Osteoporosis — FDA-approved for men and women with osteoporosis from sustained corticosteroid use.

Bone Health Research

• Fracture Healing — Research interest in accelerating fracture healing and bone repair.
• Dental Bone Regeneration — Investigated for jawbone regeneration in dental applications.